Genesys Capital

Feldan Therapeutics is a biopharmaceutical company focused on developing innovative therapies using its patented Feldan Shuttle technology. This platform facilitates rapid and secure intracellular delivery of therapeutics, expanding treatment possibilities by accessing previously unreachable cellular components. The company's current pipeline comprises clinical programs leveraging this unique technology to advance novel therapeutic applications.

Flosonics Medical is a Canadian medical device company founded in 2017, specializing in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. Its flagship product, the FloPatch, is a wearable ultrasound sensor designed to monitor blood flow in patients post-clinical intervention, thereby addressing critical clinical needs. The FloPatch is particularly beneficial for healthcare professionals, including physicians, nurses, and paramedics, operating in various high-pressure environments such as ambulances, emergency departments, operating rooms, and intensive care units. The device is notable for its portability, wireless connectivity with tablets and other medical equipment, and user-friendly functionality, all of which contribute to improved patient care in urgent medical situations. Flosonics Medical, previously known as Ke2 Technologies, rebranded in September 2017.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Giiant Pharma is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel diseases (IBD). Utilizing its proprietary Precision Delivery technology platform, Giiant designs gut-restricted, tissue-specific small molecule drug therapeutics that target various biological mechanisms in gastroenterology. The company's lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug that aims to enhance drug tolerability and improve therapeutic outcomes. By releasing the active form of the drug specifically in the colon at the site of inflammation, Giiant's approach seeks to provide safer and more effective treatment options for patients suffering from IBD.

Flosonics Medical is a Canadian medical device company founded in 2017, specializing in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. Its flagship product, the FloPatch, is a wearable ultrasound sensor designed to monitor blood flow in patients post-clinical intervention, thereby addressing critical clinical needs. The FloPatch is particularly beneficial for healthcare professionals, including physicians, nurses, and paramedics, operating in various high-pressure environments such as ambulances, emergency departments, operating rooms, and intensive care units. The device is notable for its portability, wireless connectivity with tablets and other medical equipment, and user-friendly functionality, all of which contribute to improved patient care in urgent medical situations. Flosonics Medical, previously known as Ke2 Technologies, rebranded in September 2017.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

IDbyDNA, Inc. is a biotechnology company focused on developing metagenomics technologies for the precise identification of infectious diseases. Founded in 2014 and based in Salt Lake City, Utah, the company offers its proprietary platform, Explify, which aids laboratories in detecting pathogens through a streamlined workflow. IDbyDNA provides a range of testing services, including respiratory and research services, primarily catering to hospitals, reference labs, clinical research organizations, and the biopharmaceutical industry. By integrating computational biology and artificial intelligence into its offerings, the company enhances the accuracy of nucleic acid-based microorganism detection, enabling healthcare providers to deliver comprehensive infectious disease profiles. IDbyDNA aims to improve diagnostic and treatment practices in response to the growing challenge of infectious diseases, thereby reducing related morbidity and mortality.

EBT Medical, Inc. is a clinical-stage company based in Boston, Massachusetts, with an additional office in Toronto, Canada. Founded in 2014, the company specializes in developing innovative, non-invasive neuromodulation therapies aimed at treating pelvic health disorders, particularly focusing on patients with overactive bladder. EBT Medical's technology is centered on the Saphenous nerve and is designed to provide discreet treatment options that enable patients to restore pelvic health function without the side effects typically associated with conventional therapies. The company emerged from scientific discoveries made at the University of Toronto and has benefited from a startup incubation program that has fostered numerous successful ventures in the past decade.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Canada, specializing in the development of next-generation radiopharmaceuticals as precision medicines for challenging cancers. The company leverages its Targeted Alpha Therapies platform and proprietary Fast-Clear linker technology to connect alpha particle-emitting isotopes with antibodies and other targeting molecules, enabling selective delivery of cytotoxic payloads to tumors. Its lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, Fusion is conducting preclinical studies to explore the combination of FPI-1434 with approved checkpoint inhibitors and DNA damage response inhibitors to enhance anti-tumor activity. The company is also advancing FPI-1966, aimed at treating head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014, Fusion Pharmaceuticals aims to innovate within the field of radiopharmaceuticals, transforming internalizing antibodies into effective cytotoxic drugs for improved cancer treatment outcomes.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Flosonics Medical is a Canadian medical device company founded in 2017, specializing in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. Its flagship product, the FloPatch, is a wearable ultrasound sensor designed to monitor blood flow in patients post-clinical intervention, thereby addressing critical clinical needs. The FloPatch is particularly beneficial for healthcare professionals, including physicians, nurses, and paramedics, operating in various high-pressure environments such as ambulances, emergency departments, operating rooms, and intensive care units. The device is notable for its portability, wireless connectivity with tablets and other medical equipment, and user-friendly functionality, all of which contribute to improved patient care in urgent medical situations. Flosonics Medical, previously known as Ke2 Technologies, rebranded in September 2017.

Adapsyn Bioscience, founded in 2016 and based in Hamilton, Canada, is a biotechnology company focused on discovering and developing novel medicines derived from organic biomolecules. The company's primary product is the Adapsyn platform, which utilizes proprietary algorithms and artificial intelligence to analyze genomic and metabolomic data from microbes. This platform includes several key components: PRISM for identifying natural product biosynthetic gene clusters in microbial genomes; GARLIC for defining gene clusters that encode natural product drug variants and novel candidates; GRAPE for revealing evolved drug fragments from known products; and CLAMS for matching gene clusters to mass spectrometry peaks/compounds from complex mixtures. Adapsyn Bioscience leverages these advanced bioinformatic tools and state-of-the-art laboratory facilities to support researchers in identifying a diverse range of drugs, ultimately accelerating the discovery of medicines to combat various diseases.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Canada, specializing in the development of next-generation radiopharmaceuticals as precision medicines for challenging cancers. The company leverages its Targeted Alpha Therapies platform and proprietary Fast-Clear linker technology to connect alpha particle-emitting isotopes with antibodies and other targeting molecules, enabling selective delivery of cytotoxic payloads to tumors. Its lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, Fusion is conducting preclinical studies to explore the combination of FPI-1434 with approved checkpoint inhibitors and DNA damage response inhibitors to enhance anti-tumor activity. The company is also advancing FPI-1966, aimed at treating head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014, Fusion Pharmaceuticals aims to innovate within the field of radiopharmaceuticals, transforming internalizing antibodies into effective cytotoxic drugs for improved cancer treatment outcomes.

Therapeutic Monitoring Systems Inc., established in 2007 and headquartered in Ottawa, Canada, specializes in developing bedside point-of-care clinical decision support software for hospitals' ICU and emergency departments. Its flagship product, CIMVA™, integrates with critical care monitors to analyze patient vital signs, offering novel insights into a patient's health status unavailable through standard monitoring equipment alone. The company also offers CIMVA Universal, a web-based application allowing healthcare professionals to track changes in physiological waveform variability across multiple-organ systems or parameters. Therapeutic Monitoring Systems serves clients in the United States and internationally, aiming to improve patient care and outcomes by complementing physician judgment with 'big data' analytics.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Canada, specializing in the development of next-generation radiopharmaceuticals as precision medicines for challenging cancers. The company leverages its Targeted Alpha Therapies platform and proprietary Fast-Clear linker technology to connect alpha particle-emitting isotopes with antibodies and other targeting molecules, enabling selective delivery of cytotoxic payloads to tumors. Its lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, Fusion is conducting preclinical studies to explore the combination of FPI-1434 with approved checkpoint inhibitors and DNA damage response inhibitors to enhance anti-tumor activity. The company is also advancing FPI-1966, aimed at treating head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014, Fusion Pharmaceuticals aims to innovate within the field of radiopharmaceuticals, transforming internalizing antibodies into effective cytotoxic drugs for improved cancer treatment outcomes.

Profound Medical Corp. is a medical technology company based in Mississauga, Canada, specializing in the development of innovative, incision-free therapeutic systems for the image-guided ablation of diseased tissue. The company’s flagship product, the TULSA-PRO system, integrates real-time magnetic resonance imaging with robotically driven thermal ultrasound to precisely ablate prostate tissue. Additionally, Profound Medical offers the Sonalleve platform, which is designed for treating uterine fibroids and managing palliative pain associated with bone metastases. By leveraging existing MRI infrastructure, the company aims to provide customizable and non-invasive treatment options that address the unmet needs of patients and clinicians. Profound Medical is committed to enhancing the standard of care through its advanced technologies and has established a co-development agreement with GE Healthcare to broaden access to its TULSA-PRO system.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, founded in 2005. The company is dedicated to developing innovative therapies for the treatment of pruritus and gastrointestinal diseases. Its primary product is Asimadoline, an orally active kappa opioid receptor agonist designed to alleviate itching associated with atopic dermatitis. Additionally, Tioga is focused on treating gastrointestinal conditions, with Asimadoline also aimed at addressing irritable bowel syndrome and functional dyspepsia. This drug candidate is notable for its favorable safety profile, allowing for therapeutic benefits without the typical side effects associated with mu-opioid medications.

Functional Neuromodulation, Ltd. is a medical technology company focused on developing neuromodulation therapies for cognitive and memory disorders, particularly Alzheimer's disease and mild cognitive impairment. Founded in 2010, the company is headquartered in Minneapolis, Minnesota, with an additional office in Toronto, Canada. Its primary offering is deep brain stimulation (DBS) technology, which utilizes a surgically implanted medical device to deliver mild electrical pulses to specific areas of the brain. This approach aims to enhance neural activity and modulate the brain's memory circuits, helping patients diagnosed with Alzheimer’s and other cognitive disorders to maintain a healthier quality of life.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

gIcare Pharma Inc. is a biopharmaceutical start-up based in Montreal, Canada, established in 2011. The company focuses on developing innovative gastrointestinal drugs aimed at addressing unmet medical needs in the field of gastroenterology. Led by a management team with extensive experience in this specialty, gIcare Pharma prioritizes the creation of medicines that offer significant clinical benefits to both patients and physicians, while also delivering economic advantages to third-party payers. The company’s flagship drug candidate, GIC-1001, exemplifies its commitment to innovation by integrating these multifaceted benefits into its therapeutic approach.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, founded in 2005. The company is dedicated to developing innovative therapies for the treatment of pruritus and gastrointestinal diseases. Its primary product is Asimadoline, an orally active kappa opioid receptor agonist designed to alleviate itching associated with atopic dermatitis. Additionally, Tioga is focused on treating gastrointestinal conditions, with Asimadoline also aimed at addressing irritable bowel syndrome and functional dyspepsia. This drug candidate is notable for its favorable safety profile, allowing for therapeutic benefits without the typical side effects associated with mu-opioid medications.

Allostera Pharma is a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes.

NeurAxon, Inc. is a Canadian company focused on discovering and developing therapeutics for pain management by targeting neuronal nitric oxide synthase. Founded in 2004 and headquartered in Toronto, NeurAxon is advancing a pipeline of oral products aimed at treating various pain conditions, including acute migraine, neuropathic pain, chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. By utilizing selective inhibitors of nitric oxide synthase, the company seeks to provide effective solutions for individuals suffering from these conditions.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

Millenium Biologix Corporation is a biomedical company based in Kingston, Canada, operating primarily in the United States and Europe. Founded in 1986, the company specializes in the development and commercialization of implantable medical devices and products aimed at skeletal tissue regeneration for orthopedic applications. Among its offerings is Skelite, a synthetic bone graft designed for healing and replacement purposes. Additionally, Millenium Biologix develops Primacoll and Peptos, which are intended to stimulate bone tissue growth. The company also provides ACTES, a cell culture and tissue engineering system that automates the biological processes involved in tissue engineering.

StemPath develops therapeutic solutions for modulating body's natural regenerative capacity and endogenously replacing damaged tissues with new tissues by intervention with small molecule and biological drugs. It focuses on cardiac and skeletal muscle myopathies. The company was founded in 2002 and is based in Ottawa, Canada.

NeurAxon, Inc. is a Canadian company focused on discovering and developing therapeutics for pain management by targeting neuronal nitric oxide synthase. Founded in 2004 and headquartered in Toronto, NeurAxon is advancing a pipeline of oral products aimed at treating various pain conditions, including acute migraine, neuropathic pain, chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. By utilizing selective inhibitors of nitric oxide synthase, the company seeks to provide effective solutions for individuals suffering from these conditions.

Zelos Therapeutics is a biopharmaceutical company that develops novel therapies for patients suffers from hormone-based therapeutics.